Angle Regulatory News (AGL)

ANGLE plc ("the Company")

POSTER PUBLICATION AT ESMO ON USE OF PARSORTIX SYSTEM WITH OVARIAN CANCER PATIENTS

Results further substantiate the value of the Parsortix system and its applicability in detecting ovarian cancer

ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that the Medical University of Vienna, one of its Key Opinion Leaders, has published further highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.

Further to the announcement on 21 April 2015, the Medical University of Vienna has extended the work undertaken and published results from its work with the Parsortix system at the European Cancer Congress European Society for Medical Oncology ECC 2015, 25-29 September 2015,Vienna ("ESMO"). ESMO is one of the world's largest and most influential cancer conferences with an estimated 20,000 participants.

The poster can be downloaded from the ANGLE website here http://www.angleplc.com/the-parsortix-system/download-files/. The poster describes the results of work using the Parsortix system with qPCR (quantitative real-time PCR analysis) for downstream analysis of circulating tumour cells ("Parsortix/qPCR").

The 65 patient study demonstrated the detection of ovarian cancer at 78/80% sensitivity with 100% specificity, offering the potential for a much more effective detection of ovarian cancer than traditional techniques. A larger RNA panel of markers used on a subset of patients yielded even higher sensitivity whilst retaining 100% specificity.

The new data reported at ESMO relates to a comparison of Parsortix/qPCR with conventional immune-fluorescent staining ("IF"). The main finding was that Parsortix/qPCR clearly out-performed conventional IF staining. This was particularly pronounced in ovarian cancer where IF was effective in only 25% of patients compared to 78/80% when using Parsortix/qPCR.

This work further substantiates the value of the Parsortix system and its applicability in detecting ovarian cancer. ANGLE is working with Medical University of Vienna and other leading cancer centres to demonstrate through clinical studies the capability to triage patients having surgery for abnormal pelvic mass into those with high and low risk of ovarian cancer so that they can receive appropriately targeted treatment.

ANGLE estimates that the ovarian cancer sales potential for the Parsortix system in Europe and the United States would be in excess of £300 million per annum.

Dr Eva Obermayr, Principal Investigator at the Medical University of Vienna, commented:

"The Parsortix technology clearly outperforms conventional immune-fluorescent staining. The use of qPCR with the Parsortix system is both highly sensitive and specific and offers the potential for a liquid biopsy (simple blood test) to diagnose ovarian cancer. This would greatly improve the standard of the care that can be offered to women with this condition."

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"Detection of ovarian cancer is ANGLE's first clinical application for our Parsortix system. The continued strong results from Medical University of Vienna are impressive."

For further information:

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in the United States, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi $billion clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

Now that the Parsortix system has been developed, ANGLE is focused on its commercialisation in the market.

ANGLE is strongly focused on establishing the use of the Parsortix system in clinical practice. To achieve this, ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. ANGLE believes this is the optimal approach for unlocking the multi-billion dollar worldwide market available to the Company and its potential strategic partners. Details are available here http://www.angleplc.com/the-company/collaborators/

As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For further information please visit: www.angleplc.com.